摘要
美国糖尿病协会(American Diabetes Association,ADA)和欧洲糖尿病研究协会(European Association for the Study of Diabetes,EASD)刚刚发布了更新版的《2018年2型糖尿病高血糖管理共识声明》(以下简称"新共识"),概述了2型糖尿病高血糖的管理,更新了以患者为中心的决策和支持,提出在制订降糖方案时应综合考虑2型糖尿病患者心血管与慢性肾脏病等合并症的新理念。同时,新共识也提出了关于钠-葡萄糖协同转运蛋白2抑制剂与胰高血糖素样肽-1受体激动剂的新挑战。
The American Diabetes Association(ADA)and the European Association for the Study of Diabetes(EASD)have issued an updated consensus statement outlining the management of hyperglycemia in type 2 diabetes.The report includes updated guidelines based on new literature published since 2014.Recommendations in the report highlight the importance of patient-centered decision making for glycemic management and improvement of diet and exercise for patients with type 2 diabetes through diabetes self-management education and support.For the first time,the ADA/EASD consensus report includes specific pharmacologic recommendations based on a patient's profile and health history,providing instructions in the context of atherosclerotic cardiovascular disease(ASCVD),heart failure and kidney disease.And this consensus also addresses some new issues of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists.
作者
林纬
陈刚
LIN Wei;CHEN Gang(Department of Endocrinology,FuJian Provincial Hospital,Fuzhou 350001,China)
出处
《中国医学前沿杂志（电子版）》
2018年第10期28-30,共3页
Chinese Journal of the Frontiers of Medical Science(Electronic Version)
作者简介
通讯作者:陈刚E-mail:chengangfj@163.com。
